Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
SABS Stock Chart & Stats
$4.07
$0.50(13.16%)
At close: 4:00 PM EST
$4.07
$0.50(13.16%)
Day’s Range― - ―
52-Week Range$1.00 - $6.60
Previous CloseN/A
Volume58.44K
Average Volume (3M)398.22K
Market Cap
$193.76M
Enterprise Value$15.47M
Total Cash (Recent Filing)$110.88M
Total Debt (Recent Filing)$6.19M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Mar 26, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding47,606,850
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.35
Price to Sales (P/S)26.54
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.08
Enterprise Value/Revenue134.90
Enterprise Value/Gross Profit-5.10
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$10.33Price Target Upside153.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Tc Bovine PlatformThe Tc Bovine platform is a durable technological moat: it generates fully human polyclonal antibodies suited to broadly neutralizing or multi-target indications. A platform-level advantage supports multiple programs, partnering opportunities, and potential scalability once clinical proof is achieved.
Multi-year Cash RunwayA multi-year cash runway materially reduces near-term financing pressure and supports execution of the registrational Phase 2b for SAB‑142. This funding buffer increases the odds the company can complete critical clinical milestones without immediate dilutive raises, improving execution optionality.
Strengthened Independent BoardAdding a seasoned independent chair and directors with late‑stage development/commercial expertise strengthens governance and execution capability. Improved board skillsets can accelerate regulatory readiness, commercialization planning, and strategic partnerships, reducing execution risk long term.
Bears Say
Weak Financial PerformanceSustained negative gross profit and sharply contracted revenue indicate the current business base cannot cover direct costs, producing sizable operating losses. This undermines margin sustainability and long-term self-funding ability, making the company structurally reliant on external capital until commercial scale.
Dilution Risk From New ATMA $75M ATM provides financing flexibility but formalizes ongoing reliance on equity markets and increases long-term dilution potential. Repeated use would dilute existing shareholders, can pressure equity incentives, and represents a structural funding model rather than self-sustaining cash generation.
Long, High-risk Clinical TimelineA multi-year development timeline to registrational data extends the period before potential revenue or approval. Prolonged clinical risk increases sensitivity to trial setbacks, heightens cumulative financing needs, and delays value realization, making near-term fundamentals dependent on successful trial execution.
SAB Biotherapeutics News
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $1.00 and its highest was $6.60 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
SAB Biotherapeutics’s market cap is $193.76M.
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 22 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.458 by $0.248.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -0.21.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 47,606,850 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.458. Following the earnings report the stock price went up 4.516%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Currently, no hedge funds are holding shares in SABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SAB Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (153.81% Upside)
$10.33 (153.81% Upside)
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.05%
12-Months-Change
Fundamentals
Return on Equity
-21.16%
Trailing 12-Months
Asset Growth
-51.32%
Trailing 12-Months
Company Description
SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
SABS Stock 12 Month Forecast
Average Price Target
$10.33
▲(153.81% Upside)